Our study emphasizes the need to carefully evaluate dosage-dependent efficacy when considering inhibitors for cancer treatment of USP7 and other genes that are implicated by mutational analysis as haploinsufficient tumor suppressors in some types of cancer. The gene discussed is USP7; the disease is neoplasm.